Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM on Bluesky
  • JABFM On Facebook
  • JABFM On Twitter
  • JABFM On YouTube
LetterCorrespondence

Should a Course of Prophylactic Probiotics Accompany Inpatient Antibiotic Treatment for Adults?

Vijay Venkatesan and Jay Indravadan Patel
The Journal of the American Board of Family Medicine September 2021, 34 (5) 1017; DOI: https://doi.org/10.3122/jabfm.2021.05.210158
Vijay Venkatesan
Atrium Health Carolinas Medical Center, Family Medicine Residency Program, 2001 Vail Ave Ste 400, Charlotte, NC 28207
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vkvenkatesan@outlook.com
Jay Indravadan Patel
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

To the Editor: Hospital censuses are at historic highs due to Coronavirus disease 2019 (COVID-19). As a result, we are experiencing an increased length of inpatient stays and prolonged treatments with antibiotics and steroids in our elderly patients who suffer the most from this illness.

Clostridioides difficile (“C diff”) colitis is the most common hospital-acquired infection that also has the risk factors above. It also shares a presenting symptom with COVID-19 (diarrhea) and delays recognition of comorbid disease, leading to further morbidity and mortality. Nearly every class of antibiotics, including C diff treatments, is associated with C diff infection development.1

C diff infection is a significant burden to the patient and health care system, with a 9.3% 30-day mortality rate2 and annual costs estimated at $1.5 billion in 2009.3 In 2011, in the United States, C diff attributed to 29,000 deaths alone.2

A systematic review by Goldenberg et al,4 suggested probiotic use versus placebo reduces C diff infection incidence by 60%, with a number-needed-to-treat (NNT) of 42 to prevent an infection. Rates of adverse events were not significantly different from placebo. The typical intervention used across the component studies is easy to perform in the hospital: 1 probiotic twice daily for 2 to 3 weeks or the duration of antibiotic treatment.

Notably, patients on chemotherapy were excluded from the above trials; however, a Cochrane review found no severe adverse effects associated with their use to prevent or treat chemotherapy-associated diarrhea.5 One should also not discount other benefits of probiotics, such as preventing general antibiotic-associated diarrhea (NNT of 17).4

A recent systematic review addressed the cost-effectiveness of prophylactic probiotics, with all but 1 study demonstrating the benefit of probiotic use in conjunction with antibiotics for preventing complications and hospital-acquired infections. Estimated potential savings of $500 to $2700 per patient versus placebo were reported.6 The included studies are limited by low-quality evidence.

Lack of standardization and heterogeneity of treatment remain challenges to implementing probiotic therapies in clinical practice. However, the positive results and favorable safety profiles across studies are reassuring. The regimens with the strongest evidence include S boulardii; a 2-strain combination of L acidophilus CL1285 and Lactobacillus casei LBC80R; a 3-strain combination of L acidophilus, Lactobacillus delbrueckii subsp bulgaricus, and Bifidobacterium bifidum; or the 4-strain combination of L acidophilus, L delbrueckii subsp bulgaricus, B bifidum, and Streptococcus salivarius subsp thermophilus.7

Our best method of preventing C diff infections is multifactorial—a combination of judicious antibiotic use and effective hygiene/sanitization. Based on compelling evidence, we argue for probiotic use, especially for the elderly hospitalized patient on antibiotics. Probiotics as prophylaxis for outpatient treatment in elderly populations is worth considering as well, given the safety profile and potential for preventing a potentially devastating complication.

Notes

  • Funding: The authors received no financial support for the research, authorship, or publication of this article.

  • Conflict of interest: None.

  • To see this article online, please go to: http://jabfm.org/content/34/5/1017.full.

References

  1. 1.↵
    1. Leffler DA,
    2. Lamont JT
    . Clostridium difficile infection. N Engl J Med 2015;372:1539–48.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Lessa FC,
    2. Mu Y,
    3. Bamberg WM,
    4. et al
    . Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825–34.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Zimlichman E,
    2. Henderson D,
    3. Tamir O,
    4. et al
    . Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 2013;173:2039–46.
    OpenUrl
  4. 4.↵
    1. Goldenberg JZ,
    2. Yap C,
    3. Lytvyn L,
    4. et al
    . Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017;12(12):CD006095. May 31.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Wei D,
    2. Heus P,
    3. van de Wetering FT,
    4. van Tienhoven G,
    5. Verleye L,
    6. Scholten RJ
    . Probiotics for the prevention or treatment of chemotherapy- or radiotherapy-related diarrhoea in people with cancer. Cochrane Database Syst Rev 2018;8:CD008831.
    OpenUrl
  6. 6.↵
    1. Lau VI,
    2. Rochwerg B,
    3. Xie F,
    4. et al
    . Probiotics in hospitalized adult patients: a systematic review of economic evaluations. Can J Anaesth 2020;67:247–61.
    OpenUrlPubMed
  7. 7.↵
    1. Su GL,
    2. Ko CW,
    3. Bercik P,
    4. et al
    . AGA clinical practice guidelines on the role of probiotics in the management of gastrointestinal disorders. Gastroenterol 2020;159:697–705.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

The Journal of the American Board of Family   Medicine: 34 (5)
The Journal of the American Board of Family Medicine
Vol. 34, Issue 5
September/October 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Should a Course of Prophylactic Probiotics Accompany Inpatient Antibiotic Treatment for Adults?
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Should a Course of Prophylactic Probiotics Accompany Inpatient Antibiotic Treatment for Adults?
Vijay Venkatesan, Jay Indravadan Patel
The Journal of the American Board of Family Medicine Sep 2021, 34 (5) 1017; DOI: 10.3122/jabfm.2021.05.210158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Should a Course of Prophylactic Probiotics Accompany Inpatient Antibiotic Treatment for Adults?
Vijay Venkatesan, Jay Indravadan Patel
The Journal of the American Board of Family Medicine Sep 2021, 34 (5) 1017; DOI: 10.3122/jabfm.2021.05.210158
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Notes
    • References
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Practical Clinical Topics, Digging Deeper into COVID-19, Social Determinants of Health, and Equity
  • Google Scholar

More in this TOC Section

  • Hepatitis C Treatment Knowledge, Attitudes, and Practices Among Primary Care Providers—Los Angeles County, 2023
  • Re: Factors Influencing Patient Confidence in Screening Mammography
  • Re: Physician and Advanced Practice Clinician Burnout in Rural and Urban Settings
Show more Correspondence

Similar Articles

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2025 American Board of Family Medicine

Powered by HighWire